Medication info
Subast Tablet 5mg (Rosuvastatin Calcium)

Subast Tablet 5mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/box [15 tablets/PTPX2], 300 tablets/bottle
Approval status
Active

MFDS item code 201310819 · Approved 2013.12.23 · Insurance code 643506750

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular diseases
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia : Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Older adults : No dosage adjustment is required. 4. Patients with renal impairment : No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular diseases

  • Hyperlipidemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased total cholesterol
  • increased LDL-cholesterol
  • increased Apo-B protein levels
  • cardiovascular disease risk factors
  • stroke risk
  • myocardial infarction risk
View approved original text

This medication helps patients with hyperlipidemia and dyslipidemia. It is especially used as an adjunct when dietary and exercise measures are insufficient for managing primary hyperlipidemia and mixed dyslipidemia. It is also used as an adjunct to dietary therapy in patients with homozygous familial hypercholesterolemia or primary dysbetalipoproteinemia. This medication may also be used in young patients with high LDL-cholesterol levels and cardiovascular risk factors. Additionally, it is effective in reducing the risk of cardiovascular diseases, such as stroke and myocardial infarction, in males over 50 and females over 60 with elevated high-sensitivity C-reactive protein levels and other cardiovascular risk factors. In summary, this medication is used to correct hyperlipidemia and related lipid abnormalities and to reduce cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia : Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Older adults : No dosage adjustment is required. 4. Patients with renal impairment : No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, patients who are allergic to this medication or who have severely impaired liver function should not take it. Additionally, patients with muscular diseases or severe renal impairment, as well as pregnant or breastfeeding women, should not take this medication. Women of reproductive potential should only be administered after counseling on appropriate contraception to reduce the possibility of pregnancy. Particular caution must be exercised when using this medication in patients at high risk of muscle-related side effects. For instance, patients with moderate to severe renal impairment, hypothyroidism, a family history of muscle disorders, alcohol dependence, and certain ethnicities (such as Asians) should be extra careful. Also, the risk of muscle side effects may increase when taken with certain other medications, so it is important to consult a physician. This medication contains lactose, so it should not be administered to patients with lactose intolerance or related genetic disorders. It is important to regularly monitor liver function and muscle status during treatment. If abnormal elevations in liver enzyme levels, muscle pain, or muscle weakness occur, the patient must notify their physician immediately. This medication may cause rare side effects such as interstitial lung disease, severe liver injury, and severe skin reactions, so if symptoms such as shortness of breath, rash, or jaundice occur, treatment should be discontinued and medical advice sought immediately. This medication can interact with other drugs, so if the patient is taking any other medications, they must inform their physician or pharmacist. Extra caution is needed when taken with medications that could raise the risk of muscle damage. Pregnant or nursing women should not use this medication, and women planning pregnancy should use appropriate birth control methods. In cases of overdose, there is no specific antidote, so treatment should be based on symptoms, and liver function and muscle enzyme levels must be monitored. This medication is known not to have a significant effect on driving or machinery operation, but dizziness may be a concern, so caution is needed.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, fatigue, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, drug-induced pemphigoid-like rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is best kept at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/box [15 tablets/PTPX2], 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.